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Introduction
In many cases, the development of intestinal gastric 
adenocarcinoma is the final stage of the inflammation-
atrophy-metaplasia-dysplasia-carcinoma sequence, also 
called Correa’s multi-stage cascade of gastric oncogenesis, 
a model confirmed by a considerable number of longitudi-
nal clinical-pathological and epidemiological studies [1-5]. 
According to this well-defined cascade of premalignant con-
ditions or lesions, gastric cancer (GC) develops as a result of 
a gradual progression. The first real step in the precancerous 
cascade is from the normal gastric mucosa to a chronic ac-
tive inflammation associated with Helicobacter pylori (HP) 
infection, which may persist (chronic non-atrophic gastritis 
without loss of glands) or may progress to chronic atrophic 
gastritis (CAG) – mild, moderate and severe. The next steps 
are: gastric intestinal metaplasia (IM), initially “complete” 
and then “incomplete”, and dysplasia of the gastric mucosal 
epithelium (DGME), initially low-grade and then high-gra-
de. GC is the last step in this multi-stage cascade, trigge-
red by long-term inflammatory conditions (especially HP 
infection) [3-7]. According to estimates, Correa Waterfall is 
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Abstract
Background: Independent risk factors for chronic atrophic gastritis, gastric intestinal metaplasia and gastric cancer are: Helicobacter pylori infection 
(especially virulent CagA strains), genetic factors (advanced age, reflecting the duration of Helicobacter pylori infection, male gender, family history of 
gastric cancer in first-degree relatives), gastric ulcer, biliary reflux, acute or chronic gastric inflammation, smoking, alcohol consumption, prolonged use 
of proton pump inhibitors or non-steroidal anti-inflammatory drugs, diet low in fruits, vegetables and vitamin C, excessive salt intake and consumption of 
canned foods with salt). Helicobacter pylori infection and inflammatory cells induce the expression of inducible nitric oxide synthase in the gastroduodenal 
mucosa, which causes various clinical lesions (duodenal ulcer, gastric ulcer and chronic gastritis without ulcer). Another important condition associated 
with Helicobacter pylori infection is gastric cancer. Overproduction of nitric oxide, through inducible nitric oxide synthase and oxidative stress, is a 
genotoxic and mutagenic metabolism which plays a crucial role in the process of gastric carcinogenesis.
Conclusions: Chronic atrophic gastritis is considered a multifaceted condition because it can manifest itself through a variable spectrum of nonspecific 
gastric and extra-gastric symptoms, with an overlap of the clinical features of the two entities of chronic atrophic gastritis – autoimmune and associated 
with Helicobacter pylori infection. Thus, in contrast to the classic perception of a silent condition, patients with chronic atrophic gastritis report a wide 
range of gastrointestinal symptoms, ranging from dyspeptic symptoms to those of gastroesophageal reflux.
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Material and methods
The aim of the paper is to develop a narrative synthesis 
of contemporary studies on the pathophysiology and cli-
nical picture of precancerous gastric lesions and their role 
in the development of GC. The publications were selected 
from the PubMed, Hinari and SpringerLink databases by 
keywords: chronic atrophic gastritis, gastric intestinal me-
taplasia, gastric mucosal epithelial dysplasia, gastric cancer, 
Helicobacter pylori. After processing the information from 
the databases, we selected all publications in English starting 
from January 1990. After a preliminary analysis of the titles, 
the final bibliography included original articles, editorials, 
articles of narrative synthesis, systematic and meta-analysis 
that contained information on the pathophysiology and cli-
nical picture of gastric precancerous lesions. Additionally, 
the bibliography of the selected articles was studied in or-
der to find other relevant articles on this topic. According 
to the search criteria, 563 complete articles were found. The 
final bibliography contains 46 relevant sources, which were 
considered representative for the materials published on the 
topic of this synthesis article.
Helicobacter pylori infection. HP is located in the mu-
cous layer along the surface of the gastric epithelium and in 
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the luminal portion of the gastric fovea, being rarely present 
in the deeper glands. The infection is usually contracted in 
childhood and progresses throughout life in the absence 
of proper treatment. The host responds to the presence of 
the bacterium by activating B and T lymphocytes, followed 
by infiltration of the lamina propria and gastric epithelium 
with polymorphonuclear and mononuclear inflammato-
ry cells, which phagocytose the bacterium. The release of 
toxic bacterial and inflammatory products causes damage 
to gastric epithelial cells, which progress to atrophy. Some 
glandular units develop an intestinal-type epithelium. MIG 
subsequently occurs in several areas of the atrophied gastric 
mucosa. Other glands are replaced by fibrous tissue from 
the expansion of the lamina propria. The loss of the glands 
of the gastric body produces functional changes with the 
loss of the ability to secrete acid, pepsin and intrinsic factor 
and the increase of gastric pH. There is a good, but not com-
plete, correlation between the severity of gastric mucosal 
atrophy (GMA) and depression of gastric function [9,10].
Most HP strains can be classified into 3 major types: type 
1 – highly infectious, have the gene encoding CagA antigen 
and VacA antigen, type 2 – transitional, expressing CagA an-
tigen independent of VacA antigen or vice versa and type 3 – 
with low resistance, which does not express any antigen [11].
Gastritis associated with HP infection progresses on two 
topographic models that have different clinico-pathological 
consequences. The first model, most common in Western 
countries, is antral CAG, characterized by inflammation 
located predominantly in the gastric antrum. Peptic ulcer 
usually overlaps with this type of lesion [9, 10]. The second 
model is the multifocal CAG. The special virulence of HP 
CagA-positive strains, with a predominant role in CAG and 
the evolution towards GC, is widely accepted. GMA invol-
ves the body, fundus and antral regions, with the progressive 
evolution of CAG and the gradual replacement of the gastric 
glands with intestinal-type epithelium (IM). This pattern is 
more common in developing countries and in Asia [9, 10].
Multiple studies and meta-analyses have highlighted the 
very strong association between HP infection and CAG. 
CAG develops late in the course of chronic non-atrophic 
gastritis associated with HP infection, even in HP-negative 
patients. On average, about 50% of people infected with HP 
will develop CAG of some degree or type during their life-
time. In addition, HP is also the leading cause of GC [12].
HP is the most important and significant risk factor in 
establishing CAG and IM, often associated with GCA, but 
there are other clinical, environmental, and genetic condi-
tions that are important risk factors (RF) for the progressi-
on of IM to GC. CAG is not a normal aging process, but it 
is the result of HP infection, and IM is caused by both the 
aging process and HP infection. A low risk of IM among 
HP-negative women may partially explain the lower preva-
lence of GC in women compared to men [13, 14, 15, 16]. It 
is well documented that long-term exposure to HP infecti-
on is a RF for the development, worsening and progression 
of precancerous lesions (CAG and IM). HP CagA-positive 
strains are associated with increased prevalence and severity 
of CAG and IM [14-18].
It was found that bacterial factors are important RF for 
CAG, and environmental and host factors are more impor-
tant for IM [14-18]. These include age, male gender, gastric 
ulcer, biliary reflux, severe acute and chronic gastric inflam-
mation, smoking, alcohol consumption, diet low in fruits, 
vegetables and vitamin C diet, and a high salt intake [14, 
19]. Therefore, independent RFs for CAG, IM and GC are 
considered: HP infection (especially CagA virulent strains), 
severe CAG, autoimmune CAG, certain rheumatic diseases 
(Sjögren’s syndrome), genetic factors (advanced age, which 
reflects the duration of infection with HP, male gender, fa-
mily history of GC in first-degree relatives), gastric ulcer, 
biliary reflux, severe acute and chronic gastric inflammati-
on, smoking, alcohol consumption, prolonged use of proton 
pump inhibitors or non-steroidal anti-inflammatory drugs, 
alimentation (diet low in fruits, vegetables and vitamin C, 
excessive salt intake and consumption of canned foods with 
salt) [11, 18].
A key RF of chronic inflammation is the release of lar-
ge amounts of reactive oxygen species (ROS) and reactive 
nitrogen species (RNS), which are associated with DNA 
damage and increased rates of mutations. Previous studies 
have shown that ROS and RNS, secreted by inflammatory 
and epithelial cells, can cause oxidative and nitrative dama-
ge to DNA, including the production of nitric oxide (NO) – 
a known mutagenic substance derived from inducible nitric 
oxide synthase (iNOS). Deterioration of cellular compo-
nents results in increased mutations, disorders of the func-
tions of important enzymes and proteins in premalignant 
tissues, thus contributing to the process of multistage and 
multifactorial carcinogenesis [13, 20].
NO is an important intracellular and intercellular signa-
ling molecule involved in the regulation of various physio-
logical and pathophysiological mechanisms in the cardio-
vascular, nervous and immune systems. According to expe-
rimental data, NO is normally involved in the physiological 
regulation of gastric microcirculation and its integrity. NO 
is also a SRA that acts as a cytotoxic agent in pathological 
processes, especially in inflammatory disorders, not only 
for the microorganism, but also for cells and tissues. When 
the generation of ROS and RNS exceeds the antioxidant 
capacity of the cell, they play an important role in cell da-
mage and carcinogenesis of HP-infected gastric mucosa. 
Simultaneously with oxidative damage (ROS and RNS) of 
tissue and DNA with modification of target proteins, NO 
overproduction during chronic inflammation, including 
HP infection, increases histamine secretion and the forma-
tion of carcinogenic compounds with increased risk of car-
cinogenesis (initiation and progression of carcinogenesis to 
GC). Thus, long-term inflammation of the gastric mucosa 
generates significant amounts of NO, which contributes not 
only to the deterioration of basic nucleotides in DNA and 
proteins, but, by hypermethylation of promoter sequences, 
leads to epigenetic changes in gene expression and suppre-
ssion of gene activity [1, 20-24].
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Recent advances in basic research on HP-associated car-
cinogenesis have explained that iNOS-derived NO plays a 
crucial role in the process of gastric carcinogenesis. iNOS 
expression has been reported to be absent in the normal 
gastric mucosa, increases significantly in HP-negative pa-
tients with chronic gastritis, and increases significantly in 
HP-positive patients with chronic gastritis. This expression 
is closely related to the infiltration of inflammatory cells in 
the gastric mucosa, modulates inflammation and epitheli-
al changes. In HP-positive patients, high levels of RNS in 
the gastric mucosa contribute to neoplastic transformation. 
A number of activities may contribute to the tumor-modi-
fying effects of NO, including damage to DNA and DNA-
repairing proteins, endogenous mutagenesis, increased an-
giogenesis and increased blood flow, inhibition of apoptosis 
with genetically modified cell survival, enzyme activation 
cyclooxygenase-2 and suppression of the immune system 
[14, 20].
Increased expression of iNOS has been observed in in-
flamed human gastric mucosa (in inflammatory cells – oly-
morphonuclear, plasma, lymphocytes and macrophages), as 
well as in some gastrointestinal, gynecological and central 
nervous system tumors. It is known that inflammatory cell 
infiltrate is generated in the gastric epithelium and lamina 
propria during the development of chronic gastritis, inclu-
ding chronic gastritis associated with HP. The results of the 
studies support the hypothesis that HP infection, especially 
HP CagA-positive strains and certain VacA-positive alle-
les, induces iNOS expression and activity and causes NO 
overproduction in the gastro-duodenal mucosa in order 
to regulate the inflammatory process. NO is a factor in the 
oxygen-dependent system for antiviral and antibacterial 
protection. Thus, NO has an essential role in inflammatory 
processes, but the excessive accumulation of this metaboli-
te in tissues causes toxic effect on cells, severe destructive 
changes and dysregenerative disorders. As a result, signi-
ficant destructive changes of the gastric mucosa, erosions 
and regenerative disorders, including IM, occur. However, 
the latest studies have shown that eradication of HP cau-
ses a significant reduction in iNOS expression [20-25].
In the gastrointestinal tract, excess NO aggravates mucosal 
lesions. Prolonged oxidative and nitrosative stress in severe 
CAG contributes to the development of IM and DGME and 
subsequently to intestinal GC. In atrophic gastric mucosa, 
associated with HP infection, a significant increase in iNOS 
expression and NO-modified proteins has been found, and 
hypergastrinemia is a feature of iNOS-producing gastritis, 
which has an increased risk for carcinogenesis [20-25].
Evaluation of the relationship between oxidative stress 
and early onset of GC, especially poorly differentiated intra-
mucosal adenocarcinoma in young people, revealed a signi-
ficant reduction in iNOS expression in cancer cells compa-
red to non-cancer cells, which may play an important role in 
CAG-associated carcinogenesis induced by HP [25].
In addition, research has detected an increased expressi-
on of iNOS in the gastric mucosa adjacent to HP-infected 
sites and in the non-cancerous gastric mucosa adjacent to 
intestinal cancer tissue. After successful eradication of HP, 
iNOS expression decreases. Persistence of IM, a precance-
rous lesion, is probably a source of continuous induction of 
iNOS even after eradication of HP infection [21, 22].
Therefore, HP infection induces iNOS expression in the 
gastroduodenal mucosa, an important element in lesions 
associated with HP infection. The expression of iNOS, sti-
mulated by HP and inflammatory cells, contributes to the 
mechanisms by which HP causes various clinical lesions 
(duodenal ulcer, gastric ulcer and chronic gastritis witho-
ut ulcer). Another important condition associated with HP 
infection is GC. NO is genotoxic and mutagenic, suggesting 
that NO overproduction via iNOS and ROS, derived from 
polymorphoneutrophils in HP-infected gastric mucosa, is 
involved in carcinogenesis.
Chronic atrophic gastritis. CAG is a prevalent conditi-
on, the final consequence of an inflammatory process that 
eventually leads to the loss of the corresponding mucous 
glands with reduced gastric secretory function. This his-
tological change is the result of an autoimmune-mediated 
reaction directed to parietal cells or may be associated with 
HP infection [26, 27]. 
In the last two decades there has been a wide shift in 
the paradigm of understanding GC and its premalig-
nant states from histological models to increasingly ac-
curate molecular descriptions. Despite recent advan-
ces in the molecular and cellular understanding of the 
events involved in GC, little is known about how prema-
lignant gastric lesions contribute to carcinogenesis [13].
Intestinal type GC carcinogenesis is an example of a malig-
nant disease with a well-described cascade of precancero-
us lesions (Correa cascade). GMA and IM pose a high risk 
for the development of GC, a risk that increases with the 
severity of precancerous lesions, as it is the background in 
which DGME and intestinal gastric adenocarcinoma may 
develop, although the molecular mechanisms responsible 
for this progression are not yet well understood. For this re-
ason, CAG and IM are considered the main histological pre-
cursors, which exponentially increase the risk of intestinal 
GC. However, only a minor proportion of lesions (except 
DGME) progress to cancer [3, 6, 13, 17, 28, 29]. The extent 
and topographic distribution of GMA are parallel to the risk 
of developing GC, which theoretically allows the application 
of either non-invasive (serological) or invasive (endoscopic 
/ histological) methods to quantify GMA in order to assess 
the risk of CG [30 , 31].
gastric intestinal metaplasia. Numerous studies, sys-
tematic reviews and meta-analyses have evaluated the asso-
ciation between IM and GC risk. Patients with incomplete 
IM, compared to complete IM, have a higher risk of DGME 
and GC [17, 19, 29, 32-34]. Several studies have shown that 
IM is associated with a higher risk of cancer in the gastric 
body than in the gastric antrum alone, which suggests that 
IM progresses concomitantly with GMA and predicts the 
risk of GC [19, 33]. Therefore, patients with IM, especially 
incomplete IM and in the gastric body, have a higher risk of 
GC [33].
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Dysplasia of the epithelium of the gastric mucosa. IM 
is a precursor to low-grade DGME, which can culminate 
in high-grade DGME and gastric carcinoma. DGME is the 
penultimate stage in the succession of gastric carcinoge-
nesis. This lesion is a combination of three basic morpho-
logical abnormalities: epithelial atypia without evidence of 
tissue invasion (variation in size, shape, and orientation of 
epithelial cells), loss of native epithelial engagement, and di-
sorganized glandular architecture. Thus, DGME is conside-
red a direct precancerous lesion [2, 3, 6, 28, 32, 34].
gastric cancer. The high prevalence of GC in HP-
positive subjects probably occurs because HP infection 
contributes to the progression of CAG to IM and DGME 
with a significant increase in the risk of GC [7, 12, 35]. For 
the development of GC, especially intestinal type, the end 
result of chronic inflammation caused by bacterial colo-
nization, is more important than HP infection itself [35].
The risk of developing CG depends on the degree of GMA 
at the time of eradication: it is 0.31-0.62% per year for suc-
cessful eradication of HP in cases of severe CAG (cases of 
unintentional eradication in the treatment of other infec-
tions and cases of unreported eradication) and 0.53-0.87% 
annually for cases with severe CAG and spontaneous re-
gression of HP due to CAG progression. The prevalence of 
GC in HP-negative people is extremely low – 0.66% [12]. 
Among people with IM, the cumulative rate of progressi-
on to DGME was 15% at 3 and 5 years, and the cumulative 
rates of 3, 5 and 10 years incidence of GC were 0.4%, 1.1% 
and 1.6–2.0%, respectively [32, 35]. In general, among pe-
ople with IM the annual rate of progression in GC exceeds 
0.5-1% [35].
Among 98000 patients with premalignant gastric lesions 
in the Netherlands, the average risk of GC was 2-3% over 10 
years. This risk varied concomitantly with the baseline stage 
of premalignant lesions: 0.8%, 1.8%, 3.9% and 32.7% for pa-
tients with CAG, IM, mild-to-moderate DGME and severe 
DGME, respectively [36].
All the above data suggest that there are other factors 
than GMA and IM, which have a role in gastric carcinoge-
nesis. In addition to infection with HP, CAG, and IM, there 
are several RFs for GC – sex, age, blood type, HP infection, 
family history of GC, smoking, alcohol consumption, and 
eating habits [2, 28].
Chronic atrophic gastritis symptoms. Gastritis is an in-
flammation of the gastric mucosa, most often accompanied 
by structural changes. The term gastritis most often refers to 
dyspeptic symptoms, defined as disorders of the upper gas-
trointestinal tract. Dyspepsia is the most common gastro-
intestinal problem in general practice with prevalence rates 
between 5.3% and 20.2% [37], and 20-40% of the popula-
tion report these symptoms at least once in a lifetime [38].
About 80-90% of people with HP remain asymptomatic 
throughout their lives. Chronic HP infection contributes to 
the development of CAG, which has also traditionally been 
considered asymptomatic or with nonspecific symptoms 
and diagnosed incidentally, especially autoimmune CAG 
[27, 39, 40, 41]. However, due to the marked decrease in 
gastric functional activity, dyspeptic syndrome (anorexia, 
belching, nausea, postprandial fullness and early satiety), 
bacterial overcrowding syndrome (noise and flatulence in 
the abdomen, belching, unstable stool, with frequent diar-
rhea, weight loss and anemia may occur), anemic syndro-
me, pain syndrome, dystrophic syndrome. Gastrointestinal 
manifestations are associated with non-acid reflux and are 
not specific [27, 40].
Typical symptoms of reflux (heartburn and / or acid re-
gurgitation), epigastric pain syndrome (epigastric pain and 
/ or epigastric heartburn) and postprandial distress syn-
drome (postprandial fullness and / or early satiety) were 
present at 10.5% of patients with non-atrophic gastritis or 
mild CAG, in 19.8% of patients with predominantly antral 
CAG and in 16.2% of patients with CAG predominantly in 
the gastric body. Symptoms of epigastric pain syndrome 
and postprandial distress syndrome were significantly more 
common in male patients with predominantly CAG in the 
gastric body and in female patients with predominantly an-
tral CAG. Thus, the extent and severity of CAG affect the ge-
neration of specific dyspeptic symptoms and this influence 
was different depending on gender. The reason why there is 
a gender difference in the results cannot be clearly explained 
[42].
At least one typical symptom of gastroesophageal reflux 
was reported in 24.1% of patients with CAG in the gastric 
body, including 9.2% reported epigastric heartburn and 
18.5% – regurgitation. These data showed that gastroesoph-
ageal reflux disease is present in about ¼ of these patients, 
which suggests that hypochlorhydria does not exclude, in it-
self, the occurrence of esophageal symptoms [43]. However, 
there is no correlation or overlap between symptoms and 
endoscopic or morphopathological data [44].
CAG is considered a multifaceted condition because it 
can manifest through a variable spectrum of gastric and ex-
tra-gastric symptoms. The clinical spectrum of CAG is not 
clearly defined and is often nonspecific, with an overlap of 
clinical features between the two CAG entities. Studies have 
been conducted mainly on autoimmune CAG, while data 
on the clinical presentation of CAG associated with HP in-
fection are limited [27, 45]. Thus, in contrast to the classic 
perception of a silent condition, patients with CAG report 
a wide range of gastrointestinal symptoms, ranging from 
dyspeptic symptoms to symptoms of gastroesophageal re-
flux [46].
Conclusions
1.  Independent risk factors for chronic atrophic gas-
tritis, gastric intestinal metaplasia and gastric cancer are: 
Helicobacter pylori infection (especially CagA virulent 
strains), genetic factors (advanced age, reflecting the du-
ration of Helicobacter pylori infection, male history, gastric 
cancer in first-degree relatives), gastric ulcer, biliary reflux, 
acute or chronic gastric inflammation, smoking, alcohol 
consumption, prolonged use of proton pump inhibitors or 
non-steroidal anti-inflammatory drugs, diet low in fruits, 
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vegetables and vitamin C, excessive salt intake and con-
sumption of canned foods with salt).
2. Helicobacter pylori infection and inflammatory cells 
induce the expression of inducible nitric oxide synthase in 
the gastroduodenal mucosa, which causes various clinical 
lesions (duodenal ulcer, gastric ulcer and chronic gastritis 
without ulcer). Another important condition associated 
with Helicobacter pylori infection is gastric cancer. Nitric 
oxide overproduction, through inducible nitric oxide synt-
hase and oxidative stress, is a genotoxic and mutagenic me-
tabolism with direct involvement in carcinogenesis.
3. Chronic atrophic gastritis is considered a multifaceted 
condition, because it can manifest itself through a variable 
spectrum of nonspecific gastric and extra-gastric symp-
toms, with an overlap of the clinical features of the two enti-
ties of chronic atrophic gastritis – autoimmune and associa-
ted with infection with Helicobacter pylori. Thus, in contrast 
to the classic perception of a silent condition, patients with 
chronic atrophic gastritis report a wide range of gastroin-
testinal symptoms, ranging from dyspeptic symptoms to 
symptoms of gastroesophageal reflux.
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